VRPX Virpax Pharmaceuticals
- 0.7269
- -0.0061-0.83%
- 0.6061
- -0.1208-16.62%
Virpax Pharmaceuticals News
Maxim Group Downgrades Virpax Pharmaceuticals(VRPX.US) to Hold Rating
Maxim Group Maintains Virpax Pharmaceuticals(VRPX.US) With Buy Rating, Maintains Target Price $3
Virpax Pharmaceuticals' Promising Outlook: Buy Rating Justified by Strategic Financial Management and Innovative Pain Management Pipeline
Virpax Pharmaceuticals Analyst Ratings
Virpax Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Virpax Pharmaceuticals (VRPX) and I-MAB (IMAB)
Promising Pipeline Developments and Market Opportunities Drive Buy Rating for Virpax Pharmaceuticals
Analysts Are Bullish on These Healthcare Stocks: Virpax Pharmaceuticals (VRPX), Kura Oncology (KURA)
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND) and Virpax Pharmaceuticals (VRPX)
Maxim Group Remains a Buy on Virpax Pharmaceuticals (VRPX)
Maxim Group Sticks to Their Buy Rating for Virpax Pharmaceuticals (VRPX)
Maxim Group Keeps Their Buy Rating on Virpax Pharmaceuticals (VRPX)
Analysts' Top Healthcare Picks: Xenetic Biosciences (XBIO), Virpax Pharmaceuticals (VRPX)
Maxim Group Reaffirms Their Buy Rating on Virpax Pharmaceuticals (VRPX)
Virpax Pharmaceuticals (VRPX) Receives a Buy From Maxim Group
Maxim Group Sticks to Its Buy Rating for Virpax Pharmaceuticals (VRPX)
Maxim Group Sticks to Their Buy Rating for Virpax Pharmaceuticals (VRPX)
Maxim Group Initiates Coverage on Virpax Pharmaceuticals With Buy Rating, $4 Price Target
Virpax Pharmaceuticals Price Target Announced at $4.00/Share by Maxim Group
Virpax Pharmaceuticals Initiated at Buy by Maxim Group
Analysis
Price Target
No Data
No Data